electroCore, Inc. Stock News

Randomized, open-label, hypothesis-generating study (541 participants enrolled; 250 met final analysis criteria) evaluated two proprietary non-invasive neuromodulation technologies, electroCore's cervical vagus nerve stimulation and Sonocea Sonic Augmentation Technology™ (SAT) Randomized, open-label, hypothesis-generating study (541 participants enrolled; 250 met final analysis criteria) evalua...

ROCKAWAY, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, taking place on Wednesday, November 11, 2026, at The Westin New York Grand Central in New York City.

Third quarter 2026 net sales of $9.7 million, an increase of 12% over $8.7 million  in the third quarter of 2025 Net loss of $1.3 million decreased 61% from prior year with Adjusted EBITDA net loss improving 67% from prior-year period Company to host a conference call and webcast today, November 4, 2026, at 4:30 pm EST ROCKAWAY, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq:...

ROCKAWAY, N.J., Oct. 28, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), (“electroCore” or the “Company”), a bioelectronic technology company, today announced that it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) seeking 510(k) clearance for its Quell® wearable neuromodulation platform (“Quell”) for the treatment of chronic chemotherapy-...

ROCKAWAY, N.J.,, Oct. 27, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a commercial-stage bioelectronic medicine and wellness company, today announced findings presented by the United States Air Force Research Laboratory (AFRL) of a controlled functional magnetic resonance imaging (fMRI) study evaluating transcutaneous cervical vagus nerve stimulat...

ROCKAWAY, N.J., Sept. 09, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company and leader in non-invasive vagus nerve stimulation technologies, today announced that it has appointed Joshua Lev and Mike Fox as Co-Chief Executive Officers and members of the Board of Directors, effective September 8, 2026.

Recognition highlights Truvaga's combination of patented non-invasive vagus nerve stimulation technology, thoughtful design and personalized wellness experience Recognition highlights Truvaga's combination of patented non-invasive vagus nerve stimulation technology, thoughtful design and personalized wellness experience